MyCyte

You are here: Home
Analyzing tumor cells in blood using nanomagnets
Monday, 16 July 2012
Siemens' researchers have been able to analyze blood cells by employing the same magnetic reading technology as is used for computer hard drives. They have developed a prototype for the magnetic flow cytometry of blood. Blood is the most important source of diagnostic information for doctors tracking the success of therapy for a tumor or HIV. For their new process, the researchers are taking advantage of the GMR (giant magnetoresistance) effect. The picture shows a chip which analyzes blood and provides four bit information per cell. With this information the researchers can determine the cell's diameter and the speed at which it is moving — information which allows them to make accurate conclusions about whether it is a tumor cell or not. 

Read more at: http://medicalxpress.com/news/2012-07-tumor-cells-blood-nanomagnets.html#jCp
 
Cell Sorting and Blu-ray
Monday, 18 June 2012
Sony to launch ‘Cell Sorter,’ an instrument for cell analysis which utilizes Blu-ray Disc technology

The FINANCIAL -- Sony announced that it will begin taking orders for Cell Sorter SH800 starting this fall. Cell Sorter SH800 is the first ‘flow cytometer’ cell analysis instrument developed by Sony for the optical analysis of cells.

This product successfully automates optical alignment and sorting set-up by utilizing Sony's technologies cultivated in laser optics, such as Blu-ray Disc, and optical discs. According to Sony Corporation, in addition, by incorporating a newly developed plastic cell sorting chip, it offers dramatically greater efficiency with measurement tasks.‘Flow cytometry’ is a method that applies optical measurement to analyze and sort various kinds of cells based on their size, number, exterior surface, and interior content.
 
High-throughput sequencing 1 - flow cytometry 0
Friday, 01 June 2012

Next-generation, high-speed DNA-decoding technology detects minimal residual disease in nearly double the number of leukemia patients than current gold standard method

SEATTLE – A study led by researchers at Fred Hutchinson Cancer Research Center has found that a next-generation, high-speed DNA-decoding technology called high-throughput sequencing can detect the earliest signs of potential relapse in nearly twice the number of leukemia patients as compared to flow cytometry, the current gold standard for detecting minimal residual disease. The results of the study, led by Hutchinson Center computational biologist Harlan Robins, Ph.D., are reported in the May 16 issue of Science Translational Medicine.

"The ability to predict disease relapse sooner with high-throughput sequencing would give hematologists the option to treat cancer recurrence earlier, offering a greater chance of survival. Longer term, this technology potentially also could be used to initially diagnose leukemia and lymphoma much earlier than we can today," said Robins, an associate member of the Hutchinson Center's Public Health Sciences Division and corresponding author of the paper.

 
Key Cell in treatement-resistant Asthma discovered using flow cytometry
Tuesday, 15 May 2012

ScienceDaily (May 7, 2012) — For most people with asthma, a couple of puffs from an inhaler filled with steroids makes breathing easy. But if their lungs become resistant to the calming effect of that medicine, they live in fear of severe asthma attacks that could send them to the hospital -- or worse.

Now, new research from the University of Michigan Health System may help explain what's going on in the lungs of these steroid-resistant individuals. The findings could aid the development of new treatment options, and of better ways to identify people at risk of becoming steroid-resistant.

The U-M scientists have discovered a new type of cell in mice that appears to be crucial to causing asthma symptoms -- even in the presence of steroid. The research, published in Nature Medicine, also showed that people with asthma have a very similar cell type in their blood at higher levels than people without the condition.

The researchers call the new cell type T2M, for type 2 myeloid -- reflecting its origin in the bone marrow and its involvement in the "type 2" immune response that causes asthma symptoms. In the lungs, T2M cells were shown to receive specific distress signals sent out by cells in the lung lining -- and to produce molecules that lead to more inflammation.

 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Advertisement


News Feeds and Abstracts

Products

Organizations


Standards

Educational

Upcoming Events

Job Listings